DB
ACRS icon

Dmitry Balyasny’s Aclaris Therapeutics ACRS Stock Holding History

Dmitry Balyasny’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Sell
2,023,470
-1,337,858
-40% -$5.97M 0.01% 1028
2026
Q1 		$12.6M Buy
+3,361,328
New +$11.3M 0.02% 926
2025
Q2 		– Sell
-70,502
Closed -$108K – 2746
2025
Q1 		$108K Buy
+70,502
New +$150K ﹤0.01% 2676
2024
Q3 		– Sell
-13,910
Closed -$15.3K – 2687
2024
Q2 		$15.3K Buy
+13,910
New +$16.3K ﹤0.01% 2483
2023
Q4 		– Sell
-10,511
Closed -$72K – 2437
2023
Q3 		$72K Buy
+10,511
New +$89.8K ﹤0.01% 2142
2023
Q1 		– Sell
-20,503
Closed -$323K – 2583
2022
Q4 		$323K Sell
20,503
-85,644
-81% -$1.38M ﹤0.01% 1971
2022
Q3 		$1.67M Buy
+106,147
New +$1.67M 0.01% 1580
2022
Q2 		– Sell
-209,636
Closed -$3.61M – 2696
2022
Q1 		$3.61M Sell
209,636
-256,764
-55% -$3.5M 0.01% 1089
2021
Q4 		$6.78M Buy
466,400
+304,557
+188% +$4.61M 0.02% 749
2021
Q3 		$2.91M Buy
161,843
+7,423
+5% +$119K 0.01% 1004
2021
Q2 		$2.71M Buy
+154,420
New +$3.51M 0.01% 924
2019
Q1 		– Sell
-315,167
Closed -$2.33M – 1370
2018
Q4 		$2.33M Sell
315,167
-274,833
-47% -$2.83M 0.02% 682
2018
Q3 		$8.57M Sell
590,000
-110,111
-16% -$1.89M 0.04% 538
2018
Q2 		$14M Sell
700,111
-285,865
-29% -$5.28M 0.06% 394
2018
Q1 		$17.3M Buy
985,976
+58,059
+6% +$1.23M 0.07% 363
2017
Q4 		$22.9M Buy
927,917
+461,340
+99% +$11.2M 0.07% 361
2017
Q3 		$12M Buy
466,577
+46,577
+11% +$1.25M 0.05% 444
2017
Q2 		$11.4M Buy
420,000
+21,250
+5% +$578K 0.05% 498
2017
Q1 		$11.9M Buy
398,750
+48,750
+14% +$1.41M 0.06% 431
2016
Q4 		$9.5M Buy
350,000
+250,798
+253% +$6.39M 0.05% 489
2016
Q3 		$2.54M Buy
+99,202
New +$2.1M 0.01% 591

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Dmitry Balyasny's ACRS Position: Q2 2026 in Review

Dmitry Balyasny reduced its Aclaris Therapeutics (ACRS) stake by 40% in Q2 2026, selling an estimated $5.97M and leaving 2,023,470 shares worth $10.7M. The position accounts for 0.01% of the portfolio, ranked #1028.

Dmitry Balyasny first reported a position in ACRS in Q3 2016 and has held it in 21 quarters since. The position peaked at $22.9M in Q4 2017. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Dmitry Balyasny held 2,023,470 shares of Aclaris Therapeutics worth $10.7M as of Q2 2026.
  • Dmitry Balyasny sold 1,337,858 Aclaris Therapeutics shares in Q2 2026, an estimated $5.97M.
  • Aclaris Therapeutics made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1028 holding.
  • Dmitry Balyasny first reported a position in Aclaris Therapeutics in Q3 2016 and has held it in 21 quarters since.
  • Dmitry Balyasny's Aclaris Therapeutics position peaked at $22.9M in Q4 2017.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.